AngioLab (XKRX:251280) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is AngioLab Days Payable?

AngioLab's average Accounts Payable for the six months ended in Dec. 2023 was ₩0.0 Mil. AngioLab's Cost of Goods Sold for the six months ended in Dec. 2023 was ₩395.7 Mil. Hence, AngioLab's Days Payable for the six months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for AngioLab's Days Payable or its related term are showing as below:

During the past 7 years, AngioLab's highest Days Payable was 286.65. The lowest was 57.90. And the median was 229.51.

XKRX:251280's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 150.695
* Ranked among companies with meaningful Days Payable only.

AngioLab's Days Payable stayed the same from Dec. 2021 (0.00) to Dec. 2023 (0.00).

AngioLab Days Payable Historical Data

The historical data trend for AngioLab's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Days Payable Chart

AngioLab Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

229.51

AngioLab Semi-Annual Data
	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Days Payable	Get a 7-Day Free Trial			229.51	-	-	-	-

Competitive Comparison of AngioLab's Days Payable

For the Biotechnology subindustry, AngioLab's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AngioLab's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AngioLab's Days Payable distribution charts can be found below:

* The bar in red indicates where AngioLab's Days Payable falls into.

AngioLab Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

AngioLab's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	395.72	*	365
=	0					/	395.72	*	365
=	0.00

AngioLab's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2022 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	395.72	*	365 / 2
=	0					/	395.72	*	365 / 2
=	0.00

AngioLab Days Payable Related Terms

Thank you for viewing the detailed overview of AngioLab's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AngioLab (XKRX:251280) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN

Website

http://www.angiolab.co.kr

AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines